With the recent revolution of drugs for the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC), what lessons…
Browsing: Acute Lymphoblastic Leukemia
Could being proactive, by treating lung cancer patients with next-generation drugs, help reduce the risk of acquired resistance? In this…
There are now four FDA approvals that have molecular-specific licenses for lung cancer, these include ALK rearrangements, EGFR mutations, BRAF…
How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line…
Recently, due to the revolution of immunotherapy in the treatment of nonsmall cell lung cancer (NSCLC), more drugs are being…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Idasanutlin (RG7388) is an MDM2 Antagonist Induces P53-directed apoptosis at Imedex…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Awaiting Phase 3 for Luspatercept and ASTX727 Clinical…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Sotatercept is an Active Ligand Trap Relieves repression of late-stage erythropoiesis…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Caution Using Medicine Off-Label Limits learning from clinical…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses LCL161 is a SMAC mimetic Induces Apoptosis in patients with myelofibrosis…
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Managing Relapse Patients Early On After Initial Therapy Clinical Trial Participation is Preferred…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Few Therapeutic MDS Options for Patients Incorporating novel…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at…
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Transplantation is an Option for Aggressive Lymphoma Patients w DLBL or High-Grade Lymphoma…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Novel & Combination therapies in MDS Results in…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Pentraxin 2 Analogue PRM-151,Infusion agent, anti-fibrotic therapy at Imedex Great Debates…
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains 25% of Patients Relapse Early in Follicular Lymphoma New targeted agents changes approach…
In the transplant setting, nurses are a vital component of patient care. Here, Michelle Kenyon, Vice Chair of the European…
An exciting new resource is available for nurses; The European Blood and Marrow Transplantation (EBMT) Textbook for Nurses. In this…
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center…
Advances in immunotherapy – what lung cancer patients need to know.
Dr. West discusses blaming the victim. Thanks to Steph Kang for conception, Jack West for discussion and video, Maddy Brock…
Dr. Jack West shares updates to our Lung Cancer Video Library for 2017 — Should Immunotherapy Stop in Responding Patients…
Dr. Jack West offers 2017 updates to the GRACE Lung Cancer Video Library discussion on the optimal follow-up for patients…
Dr. Nate Pennell, Director of Lung Cancer Medical Oncology at Cleveland Clinic Taussig Cancer Center shares 2017 updates for our…
We are pleased to have Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
We are pleased to have Nathan Pennell, MD, Ph.D., Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor…
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor…
Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General…
Dr. Vamsidhar Velcheti, Hematology and Medical Oncology with the Cleveland Clinic Main Campus, joined GRACE to discuss updates to our…
Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General…
Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Drs. Axel Grothey,…
Great Debates & Updates in GI Malignancies 2018 provided expert review and guidance for the evaluation and interpretation of recent…
Great Debates & Updates in GI Malignancies 2018 provided attendees with an enhanced ability to evaluate and successfully integrate optimal…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Neil Segal…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Scott Kopetz…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Tanios S.…
In Part 3 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van…
In Part 2 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van…
In Part 1 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van…
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise.
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, explains how Drugs for Long-Term is a New Area…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Rucaparib is licensed as a single-agent in…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Rucaparib, Niraparib, and Olaparib all Show Benefit. Differences…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Patients Should Still Test for BRCA Mutations…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how ARIEL3 Was a Phase 3 Trial Looking…